EDGAR Filing Documents for 0001493152-23-025606

Form 8-K - Current report:

SEC Accession No. 0001493152-23-025606

Filing Date

2023-07-26

Accepted

2023-07-26 17:25:16

Documents

Period of Report

2023-07-20

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1		form8-k.htm iXBRL	8-K	56037
2		ex2-1.htm	EX-2.1	488690
3		ex10-1.htm	EX-10.1	76493
4		ex99-1.htm	EX-99.1	17009
5		ex99-2.htm	EX-99.2	203187
6		ex99-1_001.jpg	GRAPHIC	16285
	Complete submission text file	0001493152-23-025606.txt		1170080

Data Files

Seq	Description	Document	Type	Size
7	XBRL SCHEMA FILE	qlgn-20230720.xsd	EX-101.SCH	3024
8	XBRL LABEL FILE	qlgn-20230720_lab.xml	EX-101.LAB	34240
9	XBRL PRESENTATION FILE	qlgn-20230720_pre.xml	EX-101.PRE	22365
11	EXTRACTED XBRL INSTANCE DOCUMENT	form8-k_htm.xml	XML	3221

Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011

Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165

Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)